Schrödinger’s MALT1 Inhibitor Showcases the Potential of its Computational Platform and Becomes Its First In-House Clinical Compound

SGR-1505

oral, allosteric MALT1 inhibitor Ph. I compound for mature B cell neoplasm computer-aided drug design from literature starting point ACS Spring 2024 meeting presentation Schrödinger, New York, NY

Author:

Dennis C. Koester

Reviewer:

Lew Pennington

Editor:

Matt Hesse

Schrödinger’s MALT1 Inhibitor Showcases the Potential of its Computational Platform and Becomes Its First In-House Clinical Compound

SGR-1505

Other molecules you may be interested in